This Article Full Text Full Text (PDF) All Versions of this Article: 35/8/1995    most recent 01.STR.0000135228.20619.adv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hankey, G. J. Articles by Eikelboom, J. W. Search for Related Content PubMed PubMed Citation Articles by Hankey, G. J. Articles by Eikelboom, J. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB FOLIC ACID Medline Plus Health Information Stroke Related Collections Other Treatment Other Stroke

(Stroke. 2004;35:1995.)
© 2004 American Heart Association, Inc.

Emerging Therapies

Folic Acid–Based Multivitamin Therapy to Prevent Stroke

The Jury Is Still Out

From the Stroke Unit (G.J.H.) and the Department of Haematology (J.W.E.), Royal Perth Hospital, Perth, Australia; and the School of Medicine and Pharmacology (G.J.H., J.W.E.), University of Western Australia, Crawley, Australia.

Correspondence to Dr Graeme J. Hankey, Clinical Professor, VITATOPS Trial Office, Stroke Unit, Department of Neurology, Royal Perth Hospital, 197 Wellington St, Perth, Australia 6001. E-mail gjhankey@cyllene.uwa.edu.au

Key Words: vitamin B complex • stroke prevention • folic acid • homocysteine • clinical trials

An extract of the first 250 words of the full text is provided, because this article has no abstract.

There is a large body of observational and laboratory evidence suggesting but not proving that increasing plasma concentrations of total homocysteine (tHcy) is a causal risk factor for atherothromboembolic ischemic stroke and other vascular events.^1–9

Recent publication of the results of the landmark Vitamins in Stroke Prevention (VISP) Trial is the first evidence from a large randomized controlled trial (RCT) of the effect of lowering tHcy via folic acid–based multiple B vitamin supplementation on the incidence of "hard" clinical events, such as recurrent stroke, in patients with recent ischemic stroke.^10,11 In contrast to what was expected from the epidemiological evidence, the VISP Trial did not identify a significant treatment effect of lowering tHcy by vitamin therapy on recurrent stroke, coronary events, or death, despite confirming a consistent and graded association between baseline tHcy and vascular risk (particularly the probability of stroke over time).¹¹ Recruiting primarily from North America, VISP enrolled 3680 recent (3 to 120 days) survivors of nondisabling, noncardiogenic, ischemic stroke with baseline tHcy above the 25th percentile of the North American stroke population into a double-blind, randomized comparison of high versus low doses of a combination of 12 different vitamins, including folic acid, vitamin B₁₂, vitamin B₆, and riboflavin, which are cofactors for enzymes responsible for metabolizing homocysteine.¹¹ After 2 years of follow-up, there was no significant difference in the cumulative incidence of the primary outcome event of recurrent cerebral infarction: 8.4% of 1814 patients who were allocated to high-dose multivitamins [including 2.5 mg of folic . . . [Full Text of this Article]